Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06342765

Safety and Performance of the SpineVision Posterior Fixation Systems in Thoracolumbar Spinal Treatment

The goal of this observational study is to confirm the safety and performance of the three (3) Spinevision posterior fixations systems Lumis®, Plus® and Ulis® , in the treatment of patient suffering from thoracolumbar spinal degenerative pathologies, or degenerative disc disease (disease that occurs when the spinal disk break down) associated pathologies.

Part of their standard of care, participants will be questioned on their back and leg pains, their disability and if they have encountered any adverse effects since the Spinevision posterior fixation system implant surgery. Those data will be collected up to twenty four (24) months after the Spinevision posterior fixation system implant surgery.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

DOSCEA Pôle Rachis, Bayonne, France

Loading trial locations.

About this study

The Fixed D3 study is a multicentric, non-randomized, ambispective, post market clinical follow-up study. This means that either subjects already implanted with one (1) of the Spinevision posterior fixations systems (Lumis, Plus or Ulis) - retrospective subjects - or subjects planned for treatment with one of the Spinevision posterior fixation system (prospective subjects) can be enrolled in the study.

Standard of care data up to twenty four (24) months post Spinevision posterior fixation system implant procedure will be collected; key data include back and leg Visual Analogue Score (VAS) pain, Oswestry Disability Index (ODI) score, and adverse events.

Data will be collected at pre-operative, per-operative, and post-operative Month 2, Month 6, Month 12 and Month 24.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient implanted with Lumis®, Plus® or Ulis® posterior fixation system
  • Patient of 18 years old and more
  • Patient has provided signed informed consent or did not oppose to his/her data collection, per local regulation

Exclusion criteria

contra-indication

  • trauma (i.e., fracture or dislocation)
  • Known or suspected allergy or intolerance to the implanted material, mainly to metal (e.g., cobalt, chromium, nickel, etc.)
  • Any other medical or surgical condition likely to compromise the success of instrumented surgery, such as the presence of a malignant tumor or serious congenital abnormalities, raised erythrocyte sedimentation rate not explained by other diseases, high white blood cell count or a tendency to low white blood cell count
  • All cases not described in the indications
  • Localized infection of the operative site
  • All patients with insufficient tissue cover of the operative site
  • Local signs of inflammation
  • Fever or leukocytosis
  • Pathological obesity
  • Pregnancy
  • Mental illness
  • Rapidly evolving joint diseases, bone absorption, osteopenia and/or osteoporosis. Osteoporosis is a relative contraindication, as this medical condition can limit the expected correction gain and stability of mechanical fixation
  • All cases not requiring bone graft or bone fusion
  • When pedicular screws are used, absence or malformation of pedicles
  • All cases requiring a combination of different metals
  • All patients not agreeing to comply with post-operative instructions

Treatment and study plan

Pedicle fixation surgery

Device

Pedicle fixation surgery indicates a surgical approach in the thoracic spine down to sacral spine to either support interbody fusion (fusion of the discal space between two vertebrae) , or to correct spinal deformity.

Primary outcomes

  1. Incidence of serious and non-serious device- and/or procedure-related adverse events

    Time frame: Month 24

    Rate of the serious and non-serious device- and/or procedure-related adverse events will be analyzed and compared to the state of the art.

  2. Change of the Oswestry Disability Index (ODI)

    Time frame: Month 12

    Oswestry Disability Index (ODI) mean score at Month 12 will be compared to the ODI mean score at baseline.

Secondary outcomes

  1. Fusion success

    Time frame: Month 2, month 6, month 12 and month 24

    Fusion rate will be analyzed and compared to the state if the art.

  2. Change of the Oswestry Disability Index (ODI)

    Time frame: Month 2, month 6, month 12 and month 24

    Mean Oswestry Disability Index (ODI) score evolution score will be analyzed.

  3. Change of the back and leg Visual Analogue Score (VAS)

    Time frame: Month 2, month 6, month 12 and month 24

    Back and leg Visual Analogue Score (VAS) pain assessment will be analyzed.

  4. Incidence of revision surgery at implant site

    Time frame: Month 2, month 6, month 12 and month 24

    Rate of revision surgery at implant site will be analyzed and compared to the state of the art.

Study contacts

Contact information is provided by the study sponsor or research team.

Hanta Ranaivoson

CONTACT

[email protected]

Renaud Duchenes

CONTACT

[email protected]

+33 6 86 16 61 91

Sponsors and collaborators

Lead sponsor

SPINEVISION SAS

Industry

Collaborators

  • Slb Pharma

Registry information

Official study title

Safety and Performance of the SpineVision Posterior Fixation Systems Lumis®, Plus® and Ulis® in Thoracolumbar Spinal Degenerative Pathologies or Degenerative Disc Disease (DDD) Associated Pathologies Treatment - Fixed D3 Study

Acronym: FixedD3

Important dates

Study start
2022
Primary completion
2028
Study completion
2028
First posted
Apr 2, 2024
Registry last updated
Mar 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.